Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
Tannu M, et al, PMID 39918467
Related Questions
How do you decide between administering or deferring upstream P2Y12 inhibitor treatment until patient is in the lab for NSTEMI or STEMI cases with unknown coronary anatomy?
When pursuing complex PCI of the RCA (especially when lesion preparation is required), when do you consider placing a transvenous pacemaker in anticipation of conduction abnormalities?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
Would you continue SAPT beyond 12 months after left main stenting in an elderly patient on DOAC for paroxysmal atrial fibrillation?
How do you decide between manual pressure versus opting for a specific vascular closure device at the conclusion of a femoral access case?
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
How do you approach the decision of when to perform left heart catheterization in a patient with an NSTEMI who recently had an acute ischemic stroke?
What factors influence your choice between low-dose DOAC therapy and dual antiplatelet therapy for the first 3 months after percutaneous left atrial appendage occlusion?
How would you proceed with V-A ECMO cannulation (Venous cannula) on a patient with massive PE who has an IVC filter with high thrombus burden?
